Innovation
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.
Private Company Edition: Twenty eight biopharma firms announced $2.11bn in new VC funding between Jan. 8 and 22 on top of $1.36bn in pre-J.P. Morgan disclosures on Jan. 7 and 8. Corxel led the recent financings with a $287m series D1 round to advance its oral GLP-1 agonist.
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
Interviews during the J.P. Morgan Healthcare Conference and commentary at the Biotech Showcase foresaw a strong 2026 almost across the board for drug developers seeking funding.